OmniAb, Inc.

OmniAb, Inc. (NASDAQ: OABI) is a life sciences company that became publicly traded in October 2022 through a de-SPAC business combination with Avista Public Acquisition Corp. II, sponsored by Avista Capital Holdings. The SPAC completed its initial public offering in 2021, targeting the biotechnology and life sciences sector. OmniAb was spun out of Ligand Pharmaceuticals and operates a suite of transgenic animal platforms designed to generate therapeutic antibodies for biopharmaceutical drug discovery partners. The company filed this 8-K with the SEC on November 7, 2022, shortly after completing its merger and assuming its current public identity. For full deal analytics, sponsor history, and filing data on OmniAb and the broader SPAC universe, sign up at SpacDesk.